其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

HEPES CAS Registry Number: 7365-45-9 4-羟乙基哌嗪乙磺酸

CAS Name: 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid
Additional Names: N-(2-hydroxyethyl)piperazine-N'-2-ethanesulfonic acid
Percent Composition: C 40.32%, H 7.61%, N 11.76%, O 26.86...
Literature References: One of several zwitterionic N-substituted aminosulfonic acids known as Good Buffers, active in the pH range of 6-8.5. Prepn: N. E. Good et al., Biochemistry 5, 467 (1966). Buffering characteristics: W. J. Ferguson et al., Anal. Biochem. 104, 300 (1980). Temperature effects on pKa and pH: R. N. Roy et al., Cryo-Lett. 6, 285 (1985). Interaction with hydroxyl radicals: M. Hicks, J. M. Gebicki, FEBS Lett. 199, 92 (1986). Interference with Lowry protein determination: H. M. Himmel, W. Heller, J. Clin. Chem. Clin. Biochem. 25, 909 (1987). Use as biological buffer: H. Eagle, Science 174, 500 (1971); K. V. Rao, Indian J. Exp. Biol. 15, 552 (1977); E. D. Lalague et al., J. Microsc. 127, 307 (1982); G. I. McFadden, M. Melkonian, Phycologia 25, 551 (1986).

Methysticin CAS Registry Number: 495-85-2 麻醉椒苦素

CAS Name: (6R)-6-[(1E)-2-(1,3-Benzodioxol-5-yl)ethenyl]-5,6-dihydro-4-methoxy-2H-pyran-2-one
Additional Names: 5-hydroxy-3-methoxy-7-[3,4-(methylenedioxy)phenyl]-2,6-heptadienoic acid d-lactone...
Literature References: One of the active components of the intoxicating beverage Kava from the Pacific Islands. From root of Piper methysticum Forst., Piperaceae (kava): Pomeranz, Monatsh. Chem. 10, 783 (1889); Hänsel, Beiersdorff, Arzneim.-Forsch. 9, 581 (1955). Structure: Borsche et al., Ber. 60, 2113 (1927). Synthesis of racemate: Klohs et al., J. Org. Chem. 24, 1829 (1959). Absolute config: Snatzke, Hänsel, Tetrahedron Lett. 1968, 1797. Crystal structure: P. Engel, W. Nowacki, Z. Kristallogr. 136, 437 (1972). 13C NMR: A. Banerji et al., Org. Magn. Reson. 13, 345 (1980). HPLC determn: R. M. Smith et al., J. Chromatogr. 283, 303 (1984). Anticonvulsant effects: Kretzschmar, Meyer, Arch. Int. Pharmacodyn. Ther. 177, 261 (1969). Neuroprotective activity: C. Backhauss, J. Krieglstein, Eur. J. Pharmacol. 215, 265 (1992).

Thiamine Triphosphate CAS Registry Number: 3475-65-8 [[2-[3-[(4-氨基-2-甲基嘧啶-5-基)甲基]-4-甲基-1,3-噻唑-3-鎓-5-基]乙氧基-羟基磷酰]氧基-羟基磷酰]磷酸氢酯

CAS Name: 3-[(4-Amino-2-methyl-5-pyrimidinyl)methyl]-4-methyl-5-(4,6,8,8-tetrahydroxy-3,5,7-trioxa-4,6,8-triphosphaoct-1-yl)thiazolium inner salt P,P',P''-trioxide
Additional Names: thiamine tr...
Literature References: One of the bioactive forms of thiamine; concentrated in neurons and in excitable tissues such as skeletal muscle. Believed to have a noncofactor role in nerve function. Prepn: L. Velluz et al., Bull. Soc. Chim. Fr. 15, 871 (1948); Roux et al., Bull. Soc. Chim. Biol. 30, 592 (1948); M. Viscontini et al., Helv. Chim. Acta 32, 1478 (1949). Relation to thiamine diphosphate: L. Velluz et al., J. Biol. Chem. 180, 1137 (1949). Identification in rat liver: A. Rossi-Fanelli et al., Science 116, 711 (1952). Biosynthesis by baker's yeast: K.-H. Kiessling, Nature 172, 1187 (1953). Enzymatic synthesis: J. R. Cooper, K. Nishino, Methods Enzymol. 122, 24 (1986). Chromatographic determn in brain extracts: J. R. Cooper, T. Matsuda, ibid. 20. Review of metabolism, tissue distribution and potential neurophysiological role: J. R. Cooper, J. H. Pincus, Neurochem. Res. 4, 223-239 (1979); L. Bettendorff, Metab. Brain Dis. 9, 183-209 (1994).

NADP CAS Registry Number: 53-59-8 烟酰胺腺嘌呤双核苷酸磷酸盐

CAS Name: Adenosine 5'-(trihydrogen diphosphate) 2'-(dihydrogen phosphate) P'®5'-ester with 3-(aminocarbonyl)-1-b-D-ribofuranosylpyridinium inner salt
Additional Names: 3-carbamoyl-1-b-D-ribofu...
Literature References: One of the biologically active forms of nicotinic acid, q.v. Differs from NAD, q.v., by an additional phosphate group at the 2¢-position of the adenosine moiety. Serves as a coenzyme of hydrogenases and dehydrogenases. Present in living cells primarily in the reduced form (NADPH) and is involved in synthetic reactions. Isoln from horse blood: O. Warburg et al., Biochem. Z. 282, 157 (1935); from hog liver by adsorption on charcoal: G. A. LePage, G. C. Mueller, J. Biol. Chem. 180, 975 (1949); from sheep liver by extraction with hot water: A. Kornberg, B. L. Horecker, Biochem. Prep. 3, 24 (1953); from human red blood cells by anion-exchange chromatography: G. R. Bartlett, J. Biol. Chem. 234, 449, 459 (1959). Chemical and enzymatic synthesis: D. R. Walt et al., J. Am. Chem. Soc. 106, 234 (1984). Nomenclature: M. Dixon, Science 132, 1548 (1960). Review of synthesis and metabolism: Y. Nishizuka in Method. Chim. vol. 11, F. Korte, Ed. (Academic Press, New York, 1977) pp 84-87. Review: "Niacin: Nicotinic Acid, Nicotinamide, NAD(P)" in Vitamins, W. Friedrich, Ed. (Walter de Gruyter, Berlin, 1988) pp 473-542.

Triolein CAS Registry Number: 122-32-7 甘油三油酸酯

CAS Name: 9-Octadecenoic acid 1,2,3-propanetriyl ester
Additional Names: olein; glyceryl trioleate
Percent Composition: C 77.32%, H 11.84%, O 10.84%
Literature References: One of the chief constituents of nondrying oils and fats. From Palestine olive oil: Hilditch, Madison, J. Soc. Chem. Ind. 60, 258 (1941); from cacao butter: Meara, J. Chem. Soc. 1949, 2154. Prepn by esterification of oleic acid: Wheeler et al., J. Biol. Chem. 132, 687 (1940); Swicklik et al., J. Am. Oil Chem. Soc. 32, 69 (1955). Synthesis: Serebrennikova et al., Dokl. Akad. Nauk SSSR 140, 1083 (1961).

HPA-23 CAS Registry Number: 89899-81-0

CAS Name: Hexaoctacontaoxononaantimonateheneicosatungstate(19-) heptadecaammonium disodium
Additional Names: ammonium 5-tungsto-2-antimonate; 5-tungsto-2-antimonate; 21-tungsto-9-antimonate
...
Literature References: One of the condensed mineral heteropolyanions, also called polyoxotungstates. Synthesis: M. Michelon, G. Hervé, C.R. Seances Acad. Sci. Ser. C 274, 209 (1972); M. Michelon et al., J. Inorg. Nucl. Chem. 42, 1583 (1980). Crystal structure: J. Fischer et al., J. Am. Chem. Soc. 98, 3050 (1976). Laser Raman studies of intracellular localization: C. Cibert, C. Jasmin, Biochem. Biophys. Res. Commun. 108, 1424 (1982). Antiviral activity in mice: C. Jasmin et al., J. Natl. Cancer Inst. 53, 469 (1974); G. H. Werner et al., J. Gen. Virol. 31, 59 (1976). In vitro inhibition of rabies virus: H. Tsiang et al., J. Gen. Virol. 40, 665 (1978). Effects in scrapie model systems: R. H. Kimberlin, C. A. Walker, Lancet 2, 591 (1979); eidem, Arch. Virol. 78, 9 (1983). Structure-activity study: M. Hervé et al., Biochem. Biophys. Res. Commun. 116, 222 (1983). Clinical evaluation in AIDS: W. Rozenbaum et al., Lancet 1, 450 (1985); B. L. Moskovitz, Antimicrob. Agents Chemother. 32, 1300 (1988).

Aleuritic Acid CAS Registry Number: 533-87-9 (±)-9,10,16-三羟基棕榈酸

CAS Name: (9R,10S)-rel-9,10,16-Trihydroxyhexadecanoic acid
Additional Names: 9,10,16-trihydroxypalmitic acid; 8,9,15-trihydroxypentadecane-1-carboxylic acid
Percent Composition: C 63.13%, H ...
Literature References: One of the constituent acids of shellac. Obtained in 43% yield from dewaxed shellac: Schaeffer, Gardner, Ind. Eng. Chem. 30, 333 (1938); Gidvani, J. Chem. Soc. 1944, 306; Sengupta, Bose, J. Sci. Ind. Res. 11B, 458 (1952). The acid obtained from shellac is optically inactive, although it contains two asymmetric carbon atoms. It has been shown to be the DL-erythro or dl-cis form, and is the only form described here. Synthesis of diastereoisomers: Mitter et al., Sci. Cult. 8, 273 (1942); Hunsdiecker, Ber. 76, 142 (1943); 77, 185 (1944); Baudart, Compt. Rend. 221, 205 (1945).

Gamabufotalin CAS Registry Number: 465-11-2 日蟾蜍他灵

CAS Name: (3b,5b,11a)-3,11,14-Trihydroxybufa-20,22-dienolide
Additional Names: gamabufogenin; gamabufagin
Percent Composition: C 71.61%, H 8.51%, O 19.87%
Literature References: One of the genins found in the venom of a Japanese toad (gama; Bufo vulgaris formosus). Isoln and structure: Kotake, Ann. 465, 11 (1928); Wieland, Vocke, Ann. 481, 215 (1930); Chen et al., J. Pharmacol. Exp. Ther. 49, 26 (1933); Kondo, Ohno, J. Pharm. Soc. Jpn. 59, 186 (1939); Jensen, J. Am. Chem. Soc. 59, 767 (1937); Kuno Meyer, Helv. Chim. Acta 32, 1599 (1949). Also found in Ch'an-Su, A Chinese drug prepared from Chinese toads (Bufo asiaticus = Bufo gargarizans Cantor): Ruckstuhl, Meyer, Helv. Chim. Acta 40, 1270 (1957).

Bufotalin CAS Registry Number: 471-95-4 蟾毒它灵, 蟾蜍他灵

CAS Name: (3b,5b,16b)-16-(Acetyloxy)-3,14-dihydroxybufa-20,22-dienolide
Additional Names: 3b,14,16b-trihydroxy-5b-bufa-20,22-dienolide 16-acetate
Percent Composition: C 70.24%, H 8.16%, O 21...
Literature References: One of the genins found in the venom of the common European toad (Bufo vulgaris). Isoln and structure: Faust, Arch. Exp. Pathol. Pharmakol. 47, 279 (1902); 49, 1 (1902); Wieland, Weil, Ber. 46, 3315 (1913); Wieland, Weyland, Sitzungsber. Bayer. Akad. Wiss. (math.-physikal. Klasse) 1920, 329; Wieland et al., Ann. 524, 203 (1936); Meyer, Helv. Chim. Acta 32, 1993 (1949); Pettit et al., Chem. Commun. 1970, 1566. Synthesis: G. R. Pettit et al., J. Org. Chem. 52, 3573 (1987).

Liothyronine CAS Registry Number: 6893-02-3 三碘甲状腺原氨酸

CAS Name: O-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine
Additional Names: L-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]alanine; 4-(3-iodo-4-hydroxyphenoxy)-3,5-diiodophenylalanine; 3,5,...
Literature References: One of the hormones produced by the thyroid gland that is involved in the maintenance of metabolic homeostasis. Also produced in peripheral tissues as the active metabolite of thyroxine, q.v. Identification in serum: J. Gross, R. Pitt-Rivers, Lancet I, 439 (1952). Prepn from diiodothyronine: J. Roche et al., Biochim. Biophys. Acta 11, 215 (1953). Isoln from thyroid gland and synthesis: J. Gross, R. Pitt-Rivers, Biochem. J. 53, 645 (1953). Bioactivity: eidem, ibid. 652. Elevated levels of T3 have been noted in victims of sudden infant death syndrome: G. Kocsard-Varo, Med. J. Aust. 2, 789 (1973); M. A. Chacon, J. T. Tildon, J. Pediatr. 99, 758 (1981). Direct determn in serum by RIA: I. J. Chopra et al., Thyroid 6, 255 (1996). Clinical trial in combination with thyroxine: R. Bunevicius et al., N. Engl. J. Med. 340, 424 (1999). Review of pharmacology and clinical uses: E. Sypniewski, Ann. Thorac. Surg. 56, S2-S8 (1993); of clinical trials in depression: R. Aronson et al., Arch. Gen. Psychiatry 53, 842-848 (1996); of use in heart transplantation: V. Jeevanandam, Thyroid 7, 139-145 (1997). Review of T3-receptors and molecular mechanism of action: M. A. Lazar, Endocr. Rev. 14, 184-193 (1993); G. A. Brent, N. Engl. J. Med. 331, 847-853 (1994). Review of biological effects: H. C. Freake, J. H. Oppenheimer, Annu. Rev. Nutr. 15, 263-291 (1995).